Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli / Della-Torre, E.; Campochiaro, C.; Cavalli, G.; De Luca, G.; Ciceri, F.; Zangrillo, A.; Dagna, L.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 81:9(2022), pp. E158-e158. [Epub ahead of print] [10.1136/annrheumdis-2020-218612]
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli
Della-Torre E.;Cavalli G.;De Luca G.;Ciceri F.;Zangrillo A.Penultimo
;Dagna L.Ultimo
2022-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
